compounded tirzepatide rohrersville Injectable Weight Loss in Eldersburg & Sykesville, MD led and built for women Compounded GLP-1 (Tirzepatide) Online |

10.1002/bdd.605 115

Patients with evidence of advanced fibrosis, persistently elevated liver enzymes despite lifestyle modification, or uncertainty about the underlying cause of liver disease should be referred to specialist hepatology services for further assessment and management

doi: 10.1016/j.neubiorev.2020.10.017 50

Most common side effects were gastrointestinal, with 24.5% of participants in the phase 2 obesity trial discontinuing efinopegdutide 10 mg due to AE however when the same dose was used with gradual escalation at the MASLD trial (starting dose 2.4 mg for 4 weeks, then 5 mg for 4 weeks and then 10 mg), only 5.6% of participants discontinued the medication due to AE